Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
3
50%
Ph phase_3
3
50%

Phase Distribution

3

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 3Large-scale testing
3(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(5)
Other(1)

Detailed Status

Completed5
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (50.0%)
Phase 33 (50.0%)

Trials by Status

completed583%
unknown117%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_3

A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Vaccine Compared With AZD1222

NCT05426343
completedphase_3

A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and Above

NCT05198596
completedphase_1

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901 or MVC-COV1901(Beta) Against COVID-19

NCT05216601
completedphase_3

A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults

NCT05011526
unknownphase_1

The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine

NCT05132855
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05426343Phase 3

A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Vaccine Compared With AZD1222

Completed
NCT05198596Phase 3

A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and Above

Completed
NCT05216601Phase 1

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901 or MVC-COV1901(Beta) Against COVID-19

Completed
NCT05011526Phase 3

A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults

Completed
NCT05132855Phase 1

The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine

Unknown
NCT04487210Phase 1

A Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 Against COVID-19

Completed

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6